Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TransCode Therapeutics, Inc. Common Stock (RNAZ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2400-0.0200 (-1.59%)
At close: 04:00PM EDT
1.3300 +0.07 (+5.62%)
After hours: 04:06PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    TransCode Therapeutics to Participate at BIO International Convention

    BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention Center. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scientific discoveries that it believes have the potential to significantly advance the treatmen

  • GlobeNewswire

    TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

    Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program milestone achieved in Q1 2022 BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it was awarded the second tranche of funding from a Fast-Track Small Business Innovation Resear

  • GlobeNewswire

    TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

    BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins Avenue. Virtual participation will be staged simultaneously as a live feed and available on-demand. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scien

Advertisement
Advertisement